Abstract

This grant is to provide biostatistical collaboration for the Eastern Cooperative Oncology Group. The collaborations include all appropriate activities associated with the planning, monitoring, data collection, and analysis of data obtained from clinical trials conducted by the ECOG. Research and development is also conducted on statistical and computer software methodology aimed at improving and making more efficient the planning, data management, and analysis of clinical trials in cancer.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA023318-09
Application #
3556693
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-03-01
Project End
1989-04-30
Budget Start
1985-06-01
Budget End
1986-04-30
Support Year
9
Fiscal Year
1985
Total Cost
Indirect Cost

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code

  Publications

Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Sparano, Joseph A; Gray, Robert; Oktay, Maja H et al. (2017) A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ Breast Cancer 3:42
Zhou, Jun; Mahoney, Kathleen M; Giobbie-Hurder, Anita et al. (2017) Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 5:480-492
Erbe, Amy K; Wang, Wei; Goldberg, Jacob et al. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res 23:2159-2168
Partridge, Ann H; Sepucha, Karen; O'Neill, Anne et al. (2017) Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? Breast Cancer Res Treat 165:545-553
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519

Showing the most recent 10 out of 602 publications